HPSE

Across TCGA pan-cancer cohorts, HPSE mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HPSE data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HPSE mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HPSE expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where HPSE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.339	0.648	.002	22	view →
LSCC	DFS	Tertile	III,IV	1.000	0.357	.007	13	view →
LUAD	OS	Tertile	All	0.528	0.811	.009	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HPSE–PDAC (DFS)

Open the PDAC breakdown →